Denali Therapeutics Inc (DNLI) - Total Assets
Based on the latest financial reports, Denali Therapeutics Inc (DNLI) holds total assets worth $1.27 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check DNLI capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Denali Therapeutics Inc - Total Assets Trend (2015–2025)
This chart illustrates how Denali Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Explore Denali Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Denali Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Denali Therapeutics Inc's total assets of $1.27 Billion consist of 78.7% current assets and 21.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.9% |
| Accounts Receivable | $2.18 Million | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Denali Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Denali Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Denali Therapeutics Inc's current assets represent 78.7% of total assets in 2025, a decrease from 91.1% in 2015.
- Cash Position: Cash and equivalents constituted 17.9% of total assets in 2025, down from 83.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Denali Therapeutics Inc Competitors by Total Assets
Key competitors of Denali Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Denali Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.28 | 9.56 | 26.10 |
| Quick Ratio | 9.28 | 9.56 | 26.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $912.60 Million | $786.76 Million | $1.29 Billion |
Denali Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Denali Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.45 |
| Latest Market Cap to Assets Ratio | 2.88 |
| Asset Growth Rate (YoY) | -16.7% |
| Total Assets | $1.14 Billion |
| Market Capitalization | $3.30 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Denali Therapeutics Inc's assets at a significant premium (2.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Denali Therapeutics Inc's assets decreased by 16.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Denali Therapeutics Inc (2015–2025)
The table below shows the annual total assets of Denali Therapeutics Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.14 Billion | -16.69% |
| 2024-12-31 | $1.37 Billion | +19.09% |
| 2023-12-31 | $1.15 Billion | -20.98% |
| 2022-12-31 | $1.46 Billion | +3.99% |
| 2021-12-31 | $1.40 Billion | -12.47% |
| 2020-12-31 | $1.60 Billion | +189.98% |
| 2019-12-31 | $553.23 Million | -16.43% |
| 2018-12-31 | $661.98 Million | +36.01% |
| 2017-12-31 | $486.72 Million | +79.56% |
| 2016-12-31 | $271.07 Million | +638.94% |
| 2015-12-31 | $36.68 Million | -- |
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 pr… Read more